The Deeley Research Centre (DRC) is a key site for BC Cancer’s Immunotherapy ProgramResearchers at the DRC are studying how the immune system responds to cancer and how best to enhance this response for therapeutic purposes. The Immunotherapy Program is translating discoveries from the DRC and our many collaborators into innovative clinical trials, offering promising new treatment options for patients with cancer.

Thanks to generous support of the Conconi family and thousands of other donors to the BC Cancer Foundation, as well as grants from the Canada Foundation for Innovation and the BC Knowledge Development Fund, the DRC is home to the Conconi Family Immunotherapy Lab (CFIL). CFIL is an advanced cell manufacturing facility that produces natural and genetically engineered T cell products for clinical trials in BC and other sites in Canada.

The DRC is also home to the Molecular and Cellular Immunology Core, and supports BC Cancer’s Biobanking and Biospecimen Research Services.

BC Cancer's Immunotherapy Program

The BC Cancer’s Immunotherapy Program's goal is to develop precise and potent immunotherapeutic strategies for cancer. With the generous support of the Conconi family, donors and the BCCF the DRC constructed the Conconi Family Immunotherapy Lab (CFIL). CFIL is and advanced GMP cell therapy manufacturing facility that supports the production of cellular products for immunotherapy clinical trials.   

Learn more about BC Cancer's Immunotherapy Program

Xavier Pelletier High School Internship Program

The DRC offers Grade 11 high school students a first-hand opportunity to explore cancer research. Under the guidance of DRC researchers, the students take on their own 8-week research project using the latest laboratory techniques to fight cancer.

Research Labs & Principal Investigators


News & Events

Dr. Brad Nelson – Recipient of the Canadian Society for Immunology’s 2022 Hardy Cinader Award

The Canadian Society for Immunology (CSI) has awarded Dr. Brad Nelson, distinguished scientist and co-director of BC Cancer’s Immunotherapy Program, with the prestigious 2022 Hardy Cinader Award. This award is the highest honour by the CSI, given to a Canadian scientist who exemplifies distinguished scientific leadership and accomplishments in immunology. 
Back to top